The effects of post-translational modifications on alpha-synuclein aggregation and immune cell activation in Parkinson’s disease
Zaina Khan , Yoo Jin Jung
Exploration of Neuroprotective Therapy ›› 2023, Vol. 3 ›› Issue (5) : 281 -298.
Post-translational modifications (PTMs) of alpha-synuclein (α-syn) can alter protein aggregation propensity to affect α-syn oligomer and fibril formation. The inflammatory response in Parkinson’s disease (PD) is mediated by microglia, astrocytes, T cells, B cells, macrophages, and neutrophils, which respond to α-syn aggregates in an attempt to clear synucleinopathy and restore brain homeostasis. This review focuses on the effects of PTMs on α-syn aggregation and cell-specific immune responses to α-syn aggregates in the context of PD.
Alpha-synuclein / Parkinson’s disease / neuroimmunology / post-translational modifications / protein aggregation
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
Harms AS, Ferreira SA, Romero-Ramos M. Periphery and brain, innate and adaptive immunity in Parkinson’s disease. Acta Neuropathol. 2021; 141: 527-45. |
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
Dimant H, Zhu L, Kibuuka LN, Fan Z, Hyman BT, McLean PJ. Direct visualization of CHIP-mediated degradation of alpha-synuclein in vivo: implications for PD therapeutics. PLoS One. 2014; 9: e92098. |
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
Marotta NP, Lin YH, Lewis YE, Ambroso MR, Zaro BW, Roth MT, |
| [32] |
|
| [33] |
Stone DK, |
| [34] |
|
| [35] |
Rott R, Szargel R, Shani V, Hamza H, Savyon M, Abd Elghani F, |
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
Scheiblich H, Dansokho C, Mercan D, |
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
Dzamko N, Gysbers A, Perera G, Bahar A, Shankar A, Gao J, |
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
Long H, Zhong G, Wang C, Zhang J, Zhang Y, Luo J, |
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
|
| [69] |
|
| [70] |
Konishi H, Okamoto T, Hara Y, Komine O, Tamada H, Maeda M, |
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
|
| [75] |
|
| [76] |
|
| [77] |
|
| [78] |
|
| [79] |
|
| [80] |
|
| [81] |
|
| [82] |
|
| [83] |
|
| [84] |
|
| [85] |
|
| [86] |
|
| [87] |
|
| [88] |
|
| [89] |
|
| [90] |
|
| [91] |
|
| [92] |
Gate D, Tapp E, Leventhal O, Shahid M, Nonninger TJ, Yang AC, |
| [93] |
|
| [94] |
|
| [95] |
|
| [96] |
|
| [97] |
|
| [98] |
|
| [99] |
|
| [100] |
|
| [101] |
|
| [102] |
|
| [103] |
|
| [104] |
|
| [105] |
|
| [106] |
|
| [107] |
|
| [108] |
|
| [109] |
|
| [110] |
|
| [111] |
Sekiya H, Tsuji A, Hashimoto Y, Takata M, Koga S, Nishida K, |
| [112] |
|
| [113] |
Fusco G, |
| [114] |
|
| [115] |
|
| [116] |
|
| [117] |
|
| [118] |
|
| [119] |
|
| [120] |
|
| [121] |
|
| [122] |
|
| [123] |
|
| [124] |
|
| [125] |
|
| [126] |
|
| [127] |
|
| [128] |
|
| [129] |
|
| [130] |
|
| [131] |
Lindström V, Fagerqvist T, Nordström E, Eriksson F, Lord A, Tucker S, |
| [132] |
|
| [133] |
|
| [134] |
|
| [135] |
|
| [136] |
|
| [137] |
|
/
| 〈 |
|
〉 |